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Abstract
Deep learning methods for brain tumor segmentation are typically trained in an ad hoc
fashion on all available data. Brain tumors are tremendously heterogeneous in image
appearance and labeled training data is limited. We argue that incorporation of additional
prior information, specifically tumor grade, associated with tumor imaging phenotypes
during model training can significantly improve segmentation performance. Two strategies
for incorporation of tumor grade during model training are proposed and their impact on
segmentation performance is demonstrated on the BRATS 2018 dataset.
1. Introduction
The segmentation of brain tumors has been a long standing problem in medical image anal-
ysis. Research on this topic has been accelerated greatly through the availability of public
datasets such as the Brain Tumor Segmentation (BRATS) Challenge dataset (Menze et al.,
2015; Bakas et al., 2017a,b,c). Currently, the best performing methods for brain tumor
segmentation are based on deep learning (Bakas et al., 2018), with first approaches being
applied in clinically critical areas such as tumor response assessment (Kickingereder et al.,
2019) or radiation therapy planning (Jungo et al., 2018). A general view in deep learning
is that more training data yields better generalization performance. For tasks in computer
vision it was shown that model performance increases logarithmically based on volume of
training data (Sun et al., 2017). Consequently, deep learning segmentation models are
trained on all available data, often neglecting peculiarities of the data at hand.
The BRATS Challenge has been concerned so far with the segmentation of glioma, which
are primary tumors of the central nervous system. Glioma can be classified into different
tumor grades based on the underlying molecular characteristics and histology (Louis et al.,
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2016). A higher grade reflects increasing malignancy and glioma are commonly grouped
into high-grade (grade III/IV) and low-grade glioma (grade I/II). Furthermore, they exhibit
a tremendous genetic and molecular heterogeneity which spans across tumor grades but also
manifests itself within a particular type such as glioblastoma (grade IV) (Verhaak et al.,
2010; Sottoriva et al., 2013). The underlying biological configuration of a tumor has been
associated with distinctively different tumor imaging phenotypes (Grossmann et al., 2016).
In general, low-grade glioma present much less or no contrast-enhancement compared to
high-grade glioma (Forst et al., 2014). Deep learning methods are confronted with the
challenge to successfully generalize across these different imaging phenotypes.
We hypothesize that brain tumor segmentation performance of deep learning methods
can be improved by utilizing prior information associated with tumor imaging phenotypes
during model training. Thus, we propose two simple training strategies targeted at tumor
grade and evaluate their effectiveness on the BRATS 2018 dataset using a recently proposed,
top-ranked method (McKinley et al., 2019). This work is part of a more extensive study
currently being submitted to a journal.
2. Methods
Model architecture. The deep learning method corresponds to a shallow U-Net style
model of down and upsampling connections featuring densely connected blocks of dilated
convolutions. For more details on the model architecture we refer to (McKinley et al., 2019).
Incorporation of tumor grade. We propose two strategies to utilize information on
tumor grade at the stage of model training. The first strategy consists of stratifying the
training data into high-grade glioma (HGG) and low-grade glioma (LGG) cases and training
two separate models. During testing the respective model is applied to testing data with
corresponding tumor grade. As a second strategy, we propose an injection of the tumor
grade. In addition to feeding the model with imaging data consisting of the co-registered
Magnetic Resonance (MR) sequences, we provide it with a binary input indicating if the
case at hand is either a LGG or HGG. The tumor type is injected as an image volume,
with dimensions identical to the MR sequences and all voxel values set either to zeros or
ones. The model is then trained on this enlarged dataset (type-aware network). For both
strategies, the model architecture and hyperparameter setting remains unchanged.
In the following, we utilized training data of the BRATS 2018 Challenge, which includes
75 patients with LGGs and 210 patients with HGGs. We did not include the testing data
in the analysis since tumor grade is blinded for those cases. A detailed description of the
imaging data can be found in (Bakas et al., 2018). Four different models were trained using
five-fold cross-validation: i) a baseline model using all available cases (N=285), ii) a model
trained only on HGG data (N=210), iii) a model trained only on LGG data (N=75), and
iv) the type-aware network trained on all cases (N=285).
3. Results & Conclusion
The segmentation performance of the four different deep learning models in terms of fraction
of cases with improved Dice coefficient is shown in Table 1. If we look at the HGG data
alone, the HGG model yields a significantly improved performance over the baseline model
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Table 1: Ratio in % of better performing subjects compared to baseline. p-values from a
one-sided Wilcoxon signed rank test. Bold numbers indicate statistically signifi-
cant (p < 0.05) results. (CE = contrast-enhancing tumor)
CE Core Tumor
LGG vs. Baseline 41.7 (p=0.877) 49.3 (p=0.454) 54.7 (p=0.208)
HGG vs. Baseline 58.4 (p=0.005) 70.3 (p=5.659e-09) 46.7 (p=0.877)
HGG/LGG vs. Baseline 54.6 (p=0.127) 64.9 (p=1.441e-05) 48.8 (p=0.725)
Type-aware vs. Baseline 53.4 (p=0.321) 53.9 (p=0.028) 52.6 (p=0.231)
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Figure 1: Impact of proposed strategies on model performance over all epochs. From top
left to bottom right: LGG vs. Baseline, HGG vs. Baseline, HGG/LGG vs.
Baseline, Type-aware network vs. Baseline.
in 58.4% of the cases for contrast-enhancing tumor and 70.3% of the cases for the tumor core
segmentation. Looking at all the data including also LGG, we see a significant improvement
for the tumor core segmentation in 64.9% of the cases when using the two models trained
on stratified data compared to the baseline model trained on all available data. Finally,
the type-aware network yields a minor but significant improvement for the segmentation
of the tumor core in 53.9 % of the cases. Figure 1 shows that observed improvements are
manifested relatively consistent across all epochs of model training.
We have proposed two different strategies on incorporating information of tumor grade
during model training, which are straightforward to apply, and demonstrated their effec-
tiveness on the BRATS 2018 dataset. While data stratification yields clear improvements,
more advanced network architectures incorporating prior information about tumor grade
beyond injecting it as an additional input should be investigated further. In addition, our
strategies could also be used in conjunction with networks for tumor typing.
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